SNX-5422 is not only an oral agent exhibiting strong efficacy and tolerability but also a new synthetic Hsp90 inhibitor, and it was considered as a drug with breakthrough treatment and widespread applicability in a wide range of cancers. This evidence concerns the gene HSP90AA1 and cancer.